Brand against brand · semaglutide and dulaglutide
Ozempic vs Trulicity
From the two FDA labels, read Published by PepVault
Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Trulicity is dulaglutide, a GLP-1 receptor agonist, from Eli Lilly.
FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Trulicity is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.
Label against label
| Compared | Ozempic | Trulicity |
|---|---|---|
| Active ingredient | semaglutide | dulaglutide |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen |
| How often | once a week or once a day | once a week |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 0.75 mg a week |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 4.5 mg a week |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 21.1% on 1.5 mg (placebo 5.3%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2014 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
Ozempic tablets, once a day
Trulicity, once a week (adults)

A missed dose, on each label
- Ozempic: A missed weekly injection is taken as soon as possible within 5 days. Past 5 days, the label skips it and the next dose comes on the usual day.
- Trulicity: Trulicity’s rule counts forward to the next dose: with at least 3 days (72 hours) to go, the missed dose is taken as soon as possible; with less than 3 days left, it is skipped.
The trial evidence
Questions
What is the difference between Ozempic and Trulicity?
Ozempic is semaglutide, a GLP-1 receptor agonist; Trulicity is dulaglutide, a GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Ozempic and Trulicity approved for?
Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Trulicity is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.
How often are Ozempic and Trulicity taken?
Ozempic is taken once a week or once a day, as an injection or a tablet; Trulicity once a week, as an injection.
What are the dose ranges of Ozempic and Trulicity?
On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Trulicity 0.75 mg to 4.5 mg once a week. A prescriber sets the actual dose.
What is the most common side effect of Ozempic and Trulicity?
On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Trulicity’s: nausea, 21.1% on 1.5 mg (placebo 5.3%).
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- TRULICITY (dulaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 62, published Aug 10, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- Drugs@FDA, BLA 125469 (Trulicity, the injection; application first approved 2014)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Trulicity is a trademark of its owner.